TScan Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TCRX Nasdaq 2836 www.tscan.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for TScan Therapeutics, Inc.

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Jun 22nd, 2026 5:00 am
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - Jun 3rd, 2026 7:19 am
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss - Jun 2nd, 2026 7:57 am
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates - May 6th, 2026 6:25 am
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 6th, 2026 5:00 am
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting - Apr 27th, 2026 2:30 pm
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Apr 8th, 2026 5:00 am
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space - Mar 25th, 2026 1:35 pm
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates - Mar 4th, 2026 6:15 am
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Mar 4th, 2026 5:00 am
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 - Feb 26th, 2026 5:00 am
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates - Feb 25th, 2026 10:15 am
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - Feb 25th, 2026 5:00 am
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates - Feb 12th, 2026 5:40 am
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains? - Feb 11th, 2026 5:25 am
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates - Feb 6th, 2026 6:15 am
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition - Dec 6th, 2025 3:30 pm
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities - Dec 3rd, 2025 2:05 pm
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates - Nov 12th, 2025 6:25 am
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 12th, 2025 5:00 am